Enovis (NYSE:ENOV) Insider Acquires $24,770.00 in Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 1,000 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were purchased at an average price of $24.77 per share, with a total value of $24,770.00. Following the acquisition, the insider directly owned 44,640 shares in the company, valued at approximately $1,105,732.80. This trade represents a 2.29% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Wednesday, March 4th, Oliver Engert purchased 250 shares of Enovis stock. The shares were acquired at an average cost of $25.10 per share, for a total transaction of $6,275.00.
• On Friday, February 27th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were acquired at an average price of $25.50 per share, with a total value of $25,500.00.

Enovis Trading Down 5.8%

Shares of Enovis stock traded down $1.50 during trading hours on Thursday, hitting $24.29. The company’s stock had a trading volume of 1,449,100 shares, compared to its average volume of 1,097,264. The business has a fifty day moving average of $24.15 and a 200 day moving average of $28.08. Enovis Corporation has a 1-year low of $21.00 and a 1-year high of $40.69. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $1.39 billion, a PE ratio of -1.17 and a beta of 1.46.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The firm had revenue of $575.76 million during the quarter, compared to analysts’ expectations of $584.30 million. During the same period in the prior year, the company earned $0.98 EPS. The firm’s revenue was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts forecast that Enovis Corporation will post 2.79 EPS for the current year.

Hedge Funds Weigh In On Enovis

A number of hedge funds have recently bought and sold shares of the company. River Road Asset Management LLC raised its stake in Enovis by 3.2% during the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after buying an additional 46,289 shares in the last quarter. Corient Private Wealth LLC increased its holdings in shares of Enovis by 540.7% in the 4th quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock valued at $1,470,000 after acquiring an additional 46,568 shares during the last quarter. Front Street Capital Management Inc. lifted its stake in Enovis by 75.8% during the fourth quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock worth $9,642,000 after purchasing an additional 156,069 shares during the last quarter. XTX Topco Ltd bought a new position in Enovis during the fourth quarter worth $561,000. Finally, Susquehanna Portfolio Strategies LLC boosted its holdings in Enovis by 249.9% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company’s stock worth $3,756,000 after purchasing an additional 100,704 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ENOV shares. Needham & Company LLC upped their price target on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. UBS Group reissued a “buy” rating and set a $50.00 target price on shares of Enovis in a research report on Monday, January 5th. Canaccord Genuity Group lowered their price target on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. BTIG Research lifted their price target on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, Wells Fargo & Company boosted their price objective on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Enovis currently has a consensus rating of “Moderate Buy” and an average target price of $47.43.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.